Photo: JENS KALAENE
A paediatric specialist is urging the country's drug agency to fund weight loss medication for teenagers.
A Pharmac advisory panel has provisionally recommended funding Wegovy for chronic weight management in people with high BMI's and associated conditions.
The semaglutide drug first became available here in July last year, and currently costs about $460 a month.
The advisory groups recommendation is subject to Special Authority criteria, which will limit who can prescribe it.
The recommendation has been announced after the advisory group met in December, with a full record of the meeting expected to be available by March.
But one specialist believes there are a number
Continue Reading on RNZ
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.